» Blockbuster Drug Model

Blockbuster Drug Model

1980
Pharmaceutical research laboratory focused on blockbuster drug development.

A “blockbuster drug” is a pharmaceutical product that generates more than $1 billion in annual sales for its manufacturer. This business model has historically driven the pharmaceutical industry, focusing research and development (R&D) on common, chronic conditions to maximize patent-protected revenue. This revenue funds further R&D for new drugs, creating a cycle of innovation and high profits.

The blockbuster model became the dominant strategy for large pharmaceutical companies in the late 20th century. The model relies on developing and patenting a drug that can treat a widespread chronic condition, such as high cholesterol (e.g., Lipitor), acid reflux (e.g., Prilosec), or depression (e.g., Prozac). Once approved, the company launches a massive 营销 campaign aimed at both physicians and consumers (in countries where direct-to-consumer advertising is legal). The goal is to achieve widespread prescription and capture a large market share. The drug’s 专利 provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.

UNESCO Nomenclature: 5312
– Economics of technological change

类型

Abstract System

Disruption

Incremental

使用方法

Widespread Use

Precursors

  • the bayh-dole act (1980) in the us, which encouraged commercialization of university research
  • hatch-waxman act (1984), which established the modern system of patent extensions and generic drug approvals
  • advances in molecular biology that enabled rational drug design for common disease targets
  • growth of managed care and large-scale insurance payers

应用

  • business strategy for major pharmaceutical companies (big pharma)
  • funding mechanism for large-scale r&d programs
  • marketing and sales strategies targeting large patient populations
  • justification for high drug prices during patent life

专利:

Potential Innovations Ideas

级别需要会员

您必须是!!等级!!会员才能访问此内容。

立即加入

已经是会员? 在此登录
Related to: blockbuster drug, pharmaceutical economics, big pharma, patent cliff, drug prices, r&d, marketing, lipitor, 知识产权, generic drugs.

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注

迎接新挑战
Mechanical Engineer, Project, Process Engineering or R&D Manager
有效的产品开发

可在短时间内接受新的挑战。
通过 LinkedIn 联系我
Plastic metal electronics integration, Design-to-cost, GMP, Ergonomics, Medium to high-volume devices & consumables, Lean Manufacturing, Regulated industries, CE & FDA, CAD, Solidworks, Lean Sigma Black Belt, medical ISO 13485

我们正在寻找新的赞助商

 

您的公司或机构从事技术、科学或研究吗?
> 给我们发送消息 <

接收所有新文章
免费,无垃圾邮件,电子邮件不分发也不转售

或者您可以免费获得完整会员资格以访问所有受限制的内容>这里<

Historical Context

(if date is unknown or not relevant, e.g. "fluid mechanics", a rounded estimation of its notable emergence is provided)

Related Invention, Innovation & Technical Principles

滚动至顶部

你可能还喜欢